Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk...
Company Valuation
Considering past and projected metrics, the stock is 'expensive' compared to its peers.
Target Price
The average target price of GERN is 3.4 and suggests 147% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell